(2026). Bevacizumab added to conventional induction chemotherapy for children with high risk neuroblastoma (BRAVEN trial). Discover Oncology.
Successfully copied to clipboard
Copying to clipboard failed
Chicago Style (17th ed.) Citation
"Bevacizumab Added to Conventional Induction Chemotherapy for Children with High Risk Neuroblastoma (BRAVEN Trial)."
Discover Oncology 2026.
Successfully copied to clipboard
Copying to clipboard failed
MLA (9th ed.) Citation
"Bevacizumab Added to Conventional Induction Chemotherapy for Children with High Risk Neuroblastoma (BRAVEN Trial)."
Discover Oncology, 2026.
Successfully copied to clipboard
Copying to clipboard failed
Warning: These citations may not always be 100% accurate.